Hanmi Pharmaceutical has made a deal with the global healthcare company Organon to sell three combination medicines in Malaysia and the Philippines. This expands the two companies’ partnership in Southeast Asia.
Under the deal, Hanmi will provide the medicines, and Organon will handle marketing, distribution, and sales in the local countries. The companies plan to get regulatory approval as well as launch the products in phases, and they may work together on more projects in the future.
Organon, started in 2021, is a global healthcare company with over 70 products in different medical areas. It sells medicines and medical devices in over 140 countries, including countries in Southeast Asia.
Hanmi has worked with global medicine companies before. This deal with Organon will help Hanmi grow in Southeast Asia. The pharmaceutical market there is growing fast because the population is increasing and more people have long-term illnesses. The need for combination medicines is increasing as more patients have conditions like high blood pressure.
As per Coherent Market Insights, the Healthcare Distribution Market will grow at an 6.9% compound annual growth rate (CAGR) from 2026 to 2033, from USD 1,198.00 Bn in 2026 to around USD 1,911.17 Bn by 2033. Rising healthcare costs, increasing chronic diseases, growing prevalence of lifestyle diseases, booming online distribution channels, and expanding medical infrastructure can boost demand for pharmaceutical and medical devices distribution services globally.
PADCEV (enfortumab vedotin) is a new type of cancer medicine called an antibody-drug conjugate (ADC). It targets a protein called Nectin-4, which is found on the surface of many bladder cancer cells. The medicine works by attaching to these cancer cells, entering the cells, followed by releasing a drug called MMAE. This stops the cells from bolstering as well as causes them to die.
The EV-303 trial (KEYNOTE-905) is a study testing PADCEV with Keytruda® (pembrolizumab) in patients with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy. Patients were divided into three groups: one received Keytruda alone, one had surgery only, and one received PADCEV with Keytruda before and after surgery. The combination treatment is given in 9 cycles of PADCEV and 17 cycles of Keytruda.
Moitreyee Chatterjee-Kishore, Ph.D., MBA, Executive Vice President and Head of Oncology Development, Astellas "Patients with muscle-invasive bladder cancer are at high risk of progression to metastatic disease, and those ineligible for cisplatin have historically had fewer treatment options. The EV-303 results demonstrate that enfortumab vedotin in combination with pembrolizumab can address this gap, and the CHMP's positive opinion is an important step toward making the combination available to patients who need it.”
Source:
News: Hanmi Pharmaceutical
